Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles.

Biersack B, Muthukumar Y, Schobert R, Sasse F.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6270-3. doi: 10.1016/j.bmcl.2011.09.005. Epub 2011 Sep 8.

PMID:
21963303
2.

Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.

Mahal K, Biersack B, Caysa H, Schobert R, Mueller T.

Invest New Drugs. 2015 Jun;33(3):541-54. doi: 10.1007/s10637-015-0215-9. Epub 2015 Feb 14.

PMID:
25678082
3.

Cytotoxic 2',5'-dihydroxychalcones with unexpected antiangiogenic activity.

Nam NH, Kim Y, You YJ, Hong DH, Kim HM, Ahn BZ.

Eur J Med Chem. 2003 Feb;38(2):179-87.

PMID:
12620662
4.
5.

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.

Gourdeau H, Leblond L, Hamelin B, Desputeau C, Dong K, Kianicka I, Custeau D, Boudreau C, Geerts L, Cai SX, Drewe J, Labrecque D, Kasibhatla S, Tseng B.

Mol Cancer Ther. 2004 Nov;3(11):1375-84.

6.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

7.

Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.

Petitclerc E, Deschesnes RG, Côté MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C -Gaudreault R.

Cancer Res. 2004 Jul 1;64(13):4654-63.

8.
9.

Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.

Capitosti SM, Hansen TP, Brown ML.

Bioorg Med Chem. 2004 Jan 15;12(2):327-36.

PMID:
14723953
10.

Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.

Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, van der Luit AH, de Jong D, Budde M, Bartelink H, van Blitterswijk WJ, Verheij M.

Anticancer Drugs. 2008 Jan;19(1):65-75.

PMID:
18043131
11.

Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.

Mahboobi S, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Lyssenko A, Paper DH, Bürgermeister J, Böhmer FD, Fiebig HH, Burger AM, Baasner S, Beckers T.

J Med Chem. 2001 Dec 20;44(26):4535-53.

PMID:
11741473
12.

Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.

Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E.

J Med Chem. 1992 Jun 12;35(12):2293-306.

PMID:
1613753
13.

Synthesis and cytotoxicity of 1,2-disubstituted naphth[2,3-d]imidazole-4,9-diones and related compounds.

Kuo SC, Ibuka T, Huang LJ, Lien JC, Yean SR, Huang SC, Lednicer D, Morris-Natschke S, Lee KH.

J Med Chem. 1996 Mar 29;39(7):1447-51.

PMID:
8691475
14.

Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents.

Dupeyre G, Chabot GG, Thoret S, Cachet X, Seguin J, Guénard D, Tillequin F, Scherman D, Koch M, Michel S.

Bioorg Med Chem. 2006 Jul 1;14(13):4410-26. Epub 2006 Mar 10.

PMID:
16529936
15.

Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.

Edsall AB, Mohanakrishnan AK, Yang D, Fanwick PE, Hamel E, Hanson AD, Agoston GE, Cushman M.

J Med Chem. 2004 Oct 7;47(21):5126-39.

PMID:
15456256
16.

Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.

Gangjee A, Zeng Y, Ihnat M, Warnke LA, Green DW, Kisliuk RL, Lin FT.

Bioorg Med Chem. 2005 Sep 15;13(18):5475-91.

PMID:
16039863
17.

Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.

Engel D, Nudelman A, Tarasenko N, Levovich I, Makarovsky I, Sochotnikov S, Tarasenko I, Rephaeli A.

J Med Chem. 2008 Jan 24;51(2):314-23. doi: 10.1021/jm7009827. Epub 2007 Dec 29.

PMID:
18163551
18.

Antiangiogenic activity of Bupleurum longiradiatum on human umbilical venous endothelial cells.

You YJ, Lee IS, Kim Y, Bae KH, Ahn BZ.

Arch Pharm Res. 2002 Oct;25(5):640-2.

PMID:
12433197
19.

Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerization.

Pieters L, Van Dyck S, Gao M, Bai R, Hamel E, Vlietinck A, Lemière G.

J Med Chem. 1999 Dec 30;42(26):5475-81.

PMID:
10639289
20.

Supplemental Content

Support Center